Dr. Anne-Marie C. Dingemans said the data indicate that it is safe to prescribe tarlatamab for these patients now that it has been approved by the US FDA. Read more
Presenter Dr. Bob T. Li said further study is needed, particularly given the positive PFS results in PDL-1-negative patients, who represent an unmet medical need. Read more
However, Drs. Marthe S. Paats and Anne-Marie C. Dingemans caution that in the light of the toxicity profile, the combination may not be the best option for all patients. Read more
The IASLC’s official journal now ranks second among 100 respiratory medicine journals and 13th among 322 oncology journals. Read more
When presenting the data, Dr. Benjamin Solomon said first-line lorlatinib offers unprecedented improvement in outcomes for patients with advanced ALK+ non-small cell lung cancer. Read more
Dr. Natasha Leighl said the findings of PALOMA-3 show subcutaneous dosing offers other advantages, including reduced adverse events. Read more
Dr. Tony Mok said the results of the phase III KRYSTAL-12 trial reinforce adagrasib as an effective second-line treatment option for this patient population. Read more
Drs. Joelle Fathi and Matt Evision say cytisine more than doubles the chance of cessation and its expanding accessibility heralds a new era in the management of tobacco dependency. Read more
The European Commission has approved adjuvant alectinib for ALK+ early-stage NSCLC while the US FDA has granted priority review for osimertinib for unresectable stage III EGFR+ NSCLC. Read more
Primary results from the study, presented by Dr. Suresh Ramalingam, showed osimertinib offers a significant improvement in progression-free survival following chemoradiotherapy. Read more